Tibolone is a synthetic steroid with estrogenic effects on brain, vagina and bone without stimulating the endometrium. During tibolone treatment, it is thought that the progestagenic properties of tibolone stimulate cell differentiation, which effectively counterbalances the growth-stimulating effects of the estrogenic properties of tibolone. The objective of this study was to characterize the expression profile that reflects the endometrial responses to the separated estrogenic (growth-inducing) and progestagenic (growth-inhibiting) actions of tibolone, and thus gaining insight into the counteracting effect of these properties of tibolone on the endometrium.
Introduction
Tibolone is a steroidogenic compound, which is used for hormone replacement therapy (HRT) and prevention of osteoporosis in several countries. During passage through the intestine and liver, tibolone is converted into its 3α-reduced derivative (3α-OH-tibolone), 3β-reduced derivative (3β-OH-tibolone) and 4 -isomer ( 4 -tibolone). The 3α-and 3β-hydroxy metabolites bind exclusively to the estrogen receptor, while the 4 -isomer and tibolone activate the progesterone and androgen receptors (1, 2).
The 3α-and 3β-hydroxy metabolites of tibolone have a half life of about 7h. These metabolites are also present in large amounts as sulfated metabolites, and serve as a source of estrogenic activity in tissues where sulfatases are active. Surprisingly others and we have found that the 3β-OH metabolite possesses progestagenic activity (3, 4), which may be due to the conversion of the 3β-OH metabolite back into tibolone (which has progestagenic properties), while subsequent metabolism of tibolone into the 4 -isomer is also possible. The 4 -isomer is found in low concentration and is only detectable for 6 h. In the endometrium, tibolone is locally converted into its progestagenic 4 -isomer (5). Progestagenes can induce sulfotransferase (3, 6, 7) in the endometrium and since the 3-OH metabolites are good substrates for at least 3 isoforms of sulfotransferase, this may also contribute in abrogation of the estrogenic response. It appears that the progestagenic response in the endometrium is dominant, which is confirmed by the induction of many progesterone-sensitive parameters in endometrial cells as indicated below.
In animal and human studies, it has been shown that tibolone has tissue specific effects; it acts as an estrogenic compound on bone and on the central nervous system 4 while no stimulation is found on the breast or endometrium (1, (8) (9) (10) (11) (12) (13) . In the endometrium, under physiological circumstances, estrogenic cell growth stimulation is counterbalanced by progesterone induced cell differentiation (3). During tibolone treatment, it is thought that local formation of the 4 -isomer, which has progestagenic and androgenic activity, and sulfation of the estrogenic metabolites (1, 14) , effectively counterbalances any putative adverse estrogenic effects of the 3α-and 3β-reduced derivatives of tibolone (5, [14] [15] [16] . Knowledge about the biological processes through which tibolone exerts its counterbalancing actions on the endometrium, however, is lacking (10, 14) .
The main objective of the present study was to characterize the transcription profile that reflects the endometrial response to the estrogenic (growth-inducing) and progestagenic (growth-inhibiting) metabolites of tibolone. Using this information, it was our goal to gain insight in the counteracting effect of the different activities of tibolone. The study of estrogenic and progestagenic actions of tibolone separately in one cell line which expresses both estrogen and progesterone receptors would be very difficult due to cross talk and interactions between both receptors. Therefore, we used two endometrial cell lines, which respond only to progesterone, or estrogen; PRAB-36 and ECC1. The Ishikawa PRAB-36 cell line is progesterone responsive while the ECC1 cell line is estrogen responsive. Like progesterone, tibolone inhibits growth of PRAB-36 cells, and both estrogen and tibolone are able to stimulate growth of ECC1 cells. After testing of the cell lines for their ability to convert tibolone into its metabolites, the cell lines were treated with tibolone for 6, 24 and 48 hours. The expression profiles of the cell lines at different time points were generated using a 9600 cDNA microarray. The differentially expressed genes were analyzed in order to determine which biological processes were (significantly) regulated in each cell line 5 and in each time point. Finally, to gain insight in the counterbalancing effect of tibolone, we generated a genetic network, which indicated the behavior of cellular processes in response to the progestagenic and estrogenic activities of tibolone. Growth Studies and conversion of tibolone into its metabolites was measured as described by Blok et al (4).
Materials & Methods

Cell lines
RNA isolation and gene expression profiling
Total RNA was isolated according to Blok et al (4). Microarray hybridizations were performed with the Human Unigene 1 microarray (Incyte Genomics, Inc., St.Louis, MO, USA), containing 9.600 cDNA's. Both labeling and hybridizations were performed according to previously described protocols (21).
Statistical analysis
Because most subsequent analyses depend on the accuracy of assessment of the expression ratios between the treatment and control, one of the most critical steps in microarray profiling experiments is the accurate assessment of these ratios. Spots were selected for further analysis when the signal to background ratio was greater than 2.5 and the area occupied by the signal or control on the cDNA spot on the array was greater than 40 percent. Following signal quantification, a signal correction algorithm was used to correct for systematic differences between the Cy3 and Cy5 labels. This algorithm applied a 2 nd order polynomal regression model to the data by fitting a parabola through log-transformed Cy3 versus Cy5 intensities. The resulting new data from the regression model were taken as the new gene expression ratios.
Genes that were significantly differentially expressed in the treated versus the control sample were selected by a statistical method derived from box plots, which are widely used to visualize the overall shape of a data set (Venables WN, Ripley BD. Modern
Applied Statistics with S-PLUS. second ed, 1997). In our experiments the expression of the majority of genes is not expected to differ between the treatment and the control sample and their ratios will be in the center of the distribution of expression ratios.
Therefore, we computed the 1 st (Q1) and 3 rd (Q3) quartiles of the distribution of the residuals of the regression model and the inter-quartile range (IQR) of the distribution as a measure for the variation in the expression ratios of non-differentially expressed genes. Then, in analogy with box plots, an inner fence was set at Q1-(1.58 x IQR) and Q3+(1.58 x IQR). Using these criteria, genes within the inner fence have a probability of p=0.995 to be non-differentially expressed, whereas the outlier group will harbor the differentially expressed genes. A custom visualization system was developed to display the GO classification of genes (using the GO-Mapper output) found to be of interest. By means of hierarchical tree, the context of each GO term is maintained relative to both its parents and children (if any). Further, the ratios of the numbers of genes between the two cell lines at each of the three different time points is presented graphically. The absolute 9 numbers of up and down regulated genes are included in the graphic: grouped in six pairs-split as two per cell line; three per time point.
Clustering and genetic network building
The set of genes significantly differentially expressed (p< 0.005, fold change 1.3) was clustered by the similarity of their expression profiles using a Self-Organizing Three and Gene Ontology (GO: www.geneontology.org) were imported into the pathway Assist database.
Results
I. Evaluation of the model cell lines:
Responsiveness to the hormones: cell growth study Tibolone is a compound, which, through metabolic conversion, can act on estrogen, 
Conversion of tibolone into its metabolites
In order to have an indication which metabolites were present during incubations with tibolone, the conversion of tibolone into its metabolites was measured in both cell lines by HPLC analyses. The results in Table 1 show that after 3 days of culture, tibolone is converted into the progestagenic/androgenic 4 -isomer (80% in PRAB-36
and 70% in ECC1 cells, respectively) and the estrogenic 3β-OH metabolite (19% in PRAB-36 and 27% in ECC1 cells, respectively). No 3α-OH-tibolone could be detected. 
Similarity in basal gene
II. Analyses of gene expression profiles:
Identification of up-and down-regulated genes
In Figure 2 , all obtained raw data are depicted in so-called box plots to indicate the quality of the array data. Since microarray experiments are prone to systematic variation, the high correlation between logG and logR shows that measured fluorescent intensities arise from biological differences between the RNA samples rather than systematic biases.
When all data for each cell line were compiled (6h, 24h and 48h of tibolone treatment), in total 570 genes were significantly regulated by tibolone (fold change ≥ 1.3, p<0.005). In both cell lines, the majority of genes were down regulated by tibolone (Table 2 ) and the number of genes regulated in ECC1 cells was higher than in the PRAB-36 cell line {ECC1: 385 (309+76) vs. PRAB-36: 261 (185+76)}.
In Table 3a , it is shown that in the PRAB-36 cell line, about 54 (14+40) of 112 (19+93) genes up-and down-regulated at 6 hours, were also regulated after 24 hours, and 58 (13+45) of these 112 genes were also regulated after 48 hours. The overlap in regulated genes between 24 and 48 hours is high (109 genes). In the ECC1 cell line, about 45% of the regulated genes showed regulation in more than one time point. The large overlap in number of genes between different time points in a cell line suggests that a number of biological processes are activated over a longer period of time. In Table 3b , it is shown that only a small number of genes are regulated by both progestagenic and estrogenic properties of tibolone. Interestingly, only 13% (76 genes, Table 2 ) of the significantly regulated genes were co-regulated by both progestagenic and estrogenic properties of tibolone. Opposite regulation was found in only 3.9% of the total of regulated genes (22 genes, Table 2 ).
Regulation of ER, PR and AR sensitive genes by tibolone
To identify which tibolone-regulated genes are known to be regulated by estrogens, progestagenes or androgens, we have composed a list of genes associated with these hormones and their receptors. Searching literature and public databases (including our own database) on estrogen, progesterone and androgen receptor regulated genes, 13 resulted in a list containing approximately 1500 genes. From these 1500, 922 genes were present on the Incyte array. When our 570 tibolone-regulated genes were compared to the 922 genes, 229 genes were found to overlap. As indicated in the Table 4 , of these 229 overlapping genes 58 genes were regulated in PRAB-36 cells, 131 were regulated in ECC1 cells, and 40 genes were regulated in both cell lines. The results in Table 4 show that the 4 -isomer-mediated effect (progestagenic effect on PRAB-36 cells) of tibolone predominantly affects known PR-regulated genes, while the 3β-OH-tibolone-mediated effect (estrogenic effect on ECC1 cells) of tibolone predominantly affects known ER-regulated genes. Furthermore, in the current experiments, androgenic effects of the 4 -isomer of tibolone are hardly measured:
only four AR responsive genes were identified. This indicates that, as observed in growth experiments, the androgenic effect of tibolone is negligible in our cell lines.
In the current experiments we can distinguish between two groups of genes: 229 of the tibolone-regulated genes are known, from literature or public databases, to be regulated via estrogen, progesterone or androgen receptors, and 341 genes are not known to be regulated by these hormone receptors.
Progestagenic and estrogenic effects of tibolone on cellular processes: analysis of gene categories, clustering and building genetic networks
As is observed in the Table 2 and Table 3b , only 13% of the genes are co-regulated and only 3.9% of genes are contra-regulated between the two cell lines. This indicates that the progestagenic and estrogenic properties of tibolone regulate very distinct sets of genes. The question was then raised whether the distinct expression profiles generated by the progestagenic and estrogenic properties of tibolone act at the same biological processes, or act at different biological processes.
To answer this question, for each cell line the regulated genes at three time points were compiled. Subsequently, the genes were categorized into their associated biological processes using four different programs. Table 5 analyses of genes involved in apoptosis (Fig. 3a) , proliferation and differentiation ( Fig. 3b) and transcription (Fig. 3c) . The drawback of clustering, however, is that the Finally, in order to further comprehend the response of the network to the progestagenic and estrogenic effect of tibolone, we have calculated the "net" suppressing or inducing effects of the progestagenic and estrogenic properties of tibolone on apoptosis and proliferation (Table 6) . In this analysis, we have taken into account that genes can either induce or suppress a cellular process. The results in Table 6 suggest that both progestagenic and estrogenic properties of tibolone stimulate proliferation, but they have an opposite effect on apoptosis. The progestagenic effect of tibolone stimulates apoptosis while the estrogenic effect of tibolone inhibits apoptosis. It should, however, be noted here, that a certain caution 16 with interpretation of these data is in place, since the used gene regulatory information is not based on endometrium specific data. Furthermore, all genes have been annotated a similar weight while we did not take into account that some genes are key regulators of a process while others are not.
Results from the network analysis will be evaluated further in the discussion section. Overall, these results indicated that the PRAB-36 and ECC1 cell lines are suitable models to study the separated progestagenic and estrogenic properties of tibolone administration to endometrial cells.
Discussion
Analysis of the gene expression profiles generated in the tibolone stimulated cell lines revealed that one group of regulated genes had already been recognized in literature to be regulated via estrogen or progesterone receptors (as indicated in Table 4 ), while the other group of genes were not known to be regulated by these hormone receptors. One explanation could be that tibolone regulates a tibolone-specific set of genes, however, it is also possible that the information on the public domain is not complete in this respect.
The most striking finding in the current investigations was that despite distinct expression profiles, both estrogenic and progestagenic properties of tibolone regulate similar biological processes. This suggests that the balance between the estrogenic, growth-inducing, activities and the progestagenic, differentiative and consequently growth-inhibiting, activities of tibolone in the current model can not be explained by opposed regulation of the same genes or by modulation of completely different biological processes. Most interestingly, the analysis of genetic networks and overlying the expression data on these networks (as shown in Figure 4 ) revealed that the counterbalancing effect of tibolone on cellular processes is realized through regulation of a different set of genes, and not via contra regulation of the same set of genes. Going one step further, it was shown that the actual modulation of a process is realized by differential regulation of genes with inducing or suppressing effects.
Therefore, the number of up-or down-regulated genes may not be enough to analyze whether a pathway is activated or inhibited.
As an example, we discuss hereafter the differential regulation of apoptosis and transcription by PR-and ER-mediated signaling of tibolone. The selection of the discussed genes is based on the number of connections with other genes in the network, and the consistency of their expression. Genes with a high connectivity play a vital role in the stability of a network or any other complex system (29, 30).
Differential modulation of apoptosis
Many physiological growth-control mechanisms that govern cell proliferation and tissue homeostasis are linked to apoptosis. The genetic network, as it is depicted in figure 4 , suggests a central role for apoptosis in regulation of proliferation and differentiation by tibolone. By calculating the net effect of each gene in the network on apoptosis and proliferation, we observed that both progestagenic and estrogenic properties of tibolone stimulate proliferation, but they have contra effect on apoptosis.
The progestagenic effect of tibolone stimulates apoptosis while the estrogenic effect of tibolone inhibits the apoptosis. In fact, Smid-Koopman (submitted) showed that This observation shows that in the endometrium, the specific coregulator requirements for estrogenic and progestagenic properties of tibolone are distinct. Since coregulators are themselves involved in multiple signal transduction pathways, the ability of each tibolone metabolite to modulate the expression of a specific coregulator could be a key factor underlying the counterbalancing character of tibolone. It has to be mentioned that besides regulation of expression of coregulators, other factors such as differential regulation of coregulator activity also play an important role in the determination of the biocharacter of a (synthetic) hormone. This, however, could not be studied using the current experimental setup.
As mentioned above, progesterone and estrogen receptors can indirectly regulate target gene transcription through a mechanism involving other transcription factors (38). The transcription factors SP3 and BCL6, for example are both down-regulated in PRAB-36 cells, while MYB was up-regulated in the ECC1 cell line. SP3 is a bifunctional transcription factor (transcription activator or repressor) (38, 39), which is involved in recruitment of other transcription factors to promoter regions (40);
BCL6 is a zinc finger transcription factor with cell cycle regulatory functions that can 22 inhibit apoptosis (41). MYB is a transcriptional activator and recently it was shown that the expression of IGFB5 is regulated by MYB (42).
Concluding remarks
The biological effect which tibolone treatment exerts on an endometrial cell is orchestrated by the selective expression of genes in response to tibolone's estrogenic and progestagenic properties. It seems logical that the counterbalancing effect can be realized through regulation of the same biological processes but it was intriguing to find that different genes are involved in this process and not counter regulation of the same genes.
The study of the expression dynamics of many genes simultaneously enabled us to dissect the complex genetic network that controls the patterns and rhythms of gene expression in the cells in response to tibolone treatment. However, we are aware that constructing a genetic network, based on experimental data and literature driven knowledge, is a simplification of the cellular system, and that the here selected processes (transcription, apoptosis, differentiation and proliferation) are only a part of the total biochemical network in a cell. Furthermore, not taking into account the progestagenic and estrogenic effects on the expression of each others receptors introduces a further simplification of tibolone working mechanism. On the other hand, we do think that our work helps to understand at least partly the behavior of an endometrial cellular system in response to the progestogenic and estrogenic activities of tibolone. (Table 3a) and between cell lines (Table 3b) Table 6 The numbers of up-and down-regulated genes involved in apoptosis and proliferation, and their "net" inducing or suppressing effect on each process are shown. For the calculation, we combined the number of up-and down-regulated genes and the regulatory effect of them on each of the two processes. The regulatory effect of genes was extracted from the Pathway Assist database. If a gene has positive regulatory effect on apoptosis and it is up-regulated, than the gene has an inducing effect on the apoptosis. Furthermore, we argued that if a gene has a negative regulatory effect on apoptosis and it is up-regulated, than it has a suppressing effect on the apoptosis. The net induction effect is calculated by summarizing the number of genes with a positive regulatory effect that are up-regulated and the number of genes with negative regulatory effect, which are down-regulated. The net suppression effect is calculated by summarizing the of number of genes with positive regulatory effect that are downregulated and the number of genes with negative regulatory effect, which are up-regulated.
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